3Schwartz PJ. The long QT syndrome. Curr Prob Cardiol, 1997, 22:297 -351.
4Priori SG, Schwartz PJ, Napolitano C, et 81. Risk stratification in the long- QT syndrome. N Engl J Med, 2003, 348:1866- 1874.
5Moss AJ, Zareba W, Jackson W, et 81. Effectiveness and limitations of - blocker therapy in congenital long QT syndrome. Circulation,2000,101:616 - 623.
6Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype- phenotype correlation in the long QT syndrome. Circulation, 2001,103: 89- 95.
7Shimizu W, Tanabe Y, Aiba T,et al. Differential effects of beta- blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am CoB Cardio], 2002,39(12):1984- 1991.
8Shimuzu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long QT syndromeand antagonists and sodium channel repolarization and torsade de pointes effects of beta- adrenergic agonistsblokers on transmural dispersion of Circulation, 1998,98:2313 - 2322.
9Krahn AD,Yee R, Chauhan V, et 81. Beta blockers nonnaliza QT hysteresis in Long QT syndrome. Am Heart J, 2002,143(3):528-534.
10Schwarts PJ, Priori SG, Napolitano. The Long QT Syndrome.In:Zipes DP, jalife J eds. Cardiac Eletrophysiology: From cell to bedside.3rd ed. Philadelphia:WB Saunders company, 2000.579-615.
